

# Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies

### Background

Copy Number Variations (CNVs) are prominent features of cancer cells. From a clinical standpoint, their accurate detection at a low cost is a priority. With regular increases in the number of markers to be tested, the cost effectiveness and practicality of gold standard techniques like Fluorescence In Situ Hybridization (FISH) are slowly decreasing. Costefficient Next Generation Sequencing (NGS) targeted gene panels can be scaled up but accurately detecting CNVs from the resulting data remains challenging. We demonstrate large amounts of data and machine learning can help bridge the gap between the two techniques.

### Methods

We collected the sequencing data for 6,277 patients tested using a custom amplicon based NGS assay designed to detect somatic alterations in 297 hematological cancer relevant genes such that at least one concurrent FISH test was also performed. FISH results were used to infer the gain, loss, or normality information for both the gene directly targeted by the FISH probe (reported as direct strategy in the various tables) or by using inference rules such as the observed loss of centromere 7 results in the loss of all targeted genes on chromosome 7 (reported as indirect strategy in the tables). The annotated genes were then used to curate a training set by extracting 20 features per gene from the alignment results. 10 of these features were collected from existing CNV detection methods (PureCN [1], CNVkit [2]) while 10 others are custom normalizations of the gene coverage designed to correct the high coverage variability that comes with amplicon assays. A random forest classifier was trained using this dataset. The selected model was evaluated on a distinct set of 2,738 patients sequenced using the same NGS assay and for which at least one concurrent FISH test was available.


### Results

Evaluation results are provided in the various tables on the side for both the 8 genes for which the FISH probe used to infer the gene gain, loss, or normality information directly spanned the gene region and for all 62 genes that could be evaluated using either a direct or an indirect marker. The predicted CNVs are almost a perfect match with the FISH results with a limit of detection at 20% abnormal cells. In most cases, the model reduces discordant calls by over 50% compared to using existing CNV detection software only. The last two tables allow to compare the NGS performances with the actual position of the FISH probe(s) used to label the genes and show that the concordance between NGS and FISH is maximal when compared at the exact same location. These results suggest the lower measured accuracy on some genes located far from the FISH probes may simply be a side-effect of using indirect markers to label the genes.

# Conclusion

We show the CNV detection capabilities of a targeted NGS assay can closely match the gold-standard FISH technique by analytically correcting the biases introduced by the targeting procedures. The model presented here is used to detect CNVs in ALL patients after a successful formal validation in our laboratory.

# **Study Design**



# **Complete Validation Results**

ARIC ATN ATP2 BRA CARE CBF CCN CDC2 CDK CDK CDK CDKN CSF1 CUX DDX EBF EGF EGR ERBE ETN ETV EZH FGFF GNA IKBK IKZF IRAK KMT KMT KMT KRA LUC MAP MF MY NBI NF NHP NPN NSD PDGF PIK3 PMS РОТ PRPF4 PTPN RAC RAD RHE RPS2 SAM

Christophe N. Magnan • Hyunjun Nam • Shashikant Kulkarni • Segun C. Jung NeoGenomics Laboratories, Carlsbad, CA, San Diego, CA, Houston, TX, and Aliso Viejo, CA

						Positive	Cases	<b>N</b>	legative	Cases		All Cas	ses
Gene	FISH Test	FISH Probes	Strategy	Direction	Total	Conc.	Sensitivity	Total	Conc.	Specificity	Total	Conc.	Accuracy
APC	Del(5q)	EGR1 & RPS14	Indirect	loss	164	155	94.51%	1,546	1,525	98.64%	1,710	1,680	98.25%
ARID2	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	569	99.48%	698	693	99.28%
ATM	ATM Deletion	ATM	Direct	loss	72	72	100.00%	641	629	98.13%	713	701	98.32%
ATP2A2	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	567	99.13%	698	691	99.00%
BRAF	Del(7q)	D7S2926 & D7S2460 CEN 7	Indirect Indirect	loss	106 56	106 56	100.00% 100.00%	1,602	1,581	98.69% 96.02%	1,708	1,687 1,649	98.77% 96.15%
CARD11	Monosomy 7 Monosomy 7	CEN 7 CEN 7	Indirect	loss loss	56	50	92.86%	1,659 1,659	1,593 1,636	96.02%	1,715 1,715	1,649	98.15% 98.43%
CBFB	Rearrangement	CBFB	Direct	loss	23	22	95.65%	517	506	97.87%	540	528	97.78%
CCND2	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	565	98.78%	698	689	98.71%
CDC25C	Del(5q)	EGR1 & RPS14	Indirect	loss	164	161	98.17%	1,546	1,533	99.16%	1,710	1,694	99.06%
CDK2	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	564	98.60%	698	688	98.57%
CDK4	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	567	99.13%	698	691	99.00%
CDK6	Del(7q)	D7S2926 & D7S2460	Indirect	loss	106	100	94.34%	1,602	1,583	98.81%	1,708	1,683	98.54%
	Monosomy 7	CEN 7	Indirect	loss	56	55	98.21%	1,659	1,599	96.38%	1,715	1,654	96.44%
CDKN1B CSF1R	Trisomy 12 Del(5q)	CEN 12 EGR1 & RPS14	Indirect Indirect	gain loss	126 164	124 162	98.41% 98.78%	572 1,546	564 1,538	98.60% 99.48%	698 1,710	688 1,700	98.57% 99.42%
	Del(7q)	D7S2926 & D7S2460	Indirect	loss	104	102	97.17%	1,602	1,558	98.06%	1,708	1,674	99.42 <i>%</i> 98.01%
CUX1	Monosomy 7	CEN 7	Indirect	loss	56	55	98.21%	1,659	1,583	95.42%	1,715	1,638	95.51%
DDX41	Del(5q)	EGR1 & RPS14	Indirect	loss	164	143	87.20%	1,546	1,528	98.84%	1,710	1,671	97.72%
EBF1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	151	92.07%	1,546	1,477	95.54%	1,710	1,628	95.20%
EGFR	Monosomy 7	CEN 7	Indirect	loss	56	54	96.43%	1,659	1,621	97.71%	1,715	1,675	97.67%
EGR1	Del(5q)	EGR1	Direct	loss	171	169	98.83%	1,541	1,538	99.81%	1,712	1,707	99.71%
	Del(5q)	EGR1 & RPS14	Indirect	loss	164	162	98.78%	1,546	1,538	99.48%	1,710	1,700	99.42%
ERBB3	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	563	98.43%	698	687	98.42%
ETNK1 ETV6	Trisomy 12 Trisomy 12	CEN 12 CEN 12	Indirect Indirect	gain gain	126 126	124 124	98.41% 98.41%	572 572	564 568	98.60% 99.30%	698 698	688 692	98.57% 99.14%
	Del(7q)	D7S2926 & D7S2460	Indirect	gain loss	126	124	98.41% 98.11%	1,602	568 1,579	99.30%	698 1,708	692 1,683	99.14% 98.54%
EZH2	Monosomy 7	CEN 7	Indirect	loss	56	55	98.11%	1,659	1,593	96.02%	1,708	1,648	96.09%
FGFR1	Trisomy 8	CEN 8	Indirect	gain	93	86	92.47%	1,590	1,590	100.00%	1,683	1,676	99.58%
GNA12	Monosomy 7	CEN 7	Indirect	loss	56	51	91.07%	1,659	1,600	96.44%	1,715	1,651	96.27%
IKBKB	Trisomy 8	CEN 8	Indirect	gain	93	89	95.70%	1,590	1,575	99.06%	1,683	1,664	98.87%
IKZF1	Monosomy 7	CEN 7	Indirect	loss	56	54	96.43%	1,659	1,603	96.62%	1,715	1,657	96.62%
IRAK4	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	568	99.30%	698	692	99.14%
KMT2A	Rearrangement	KMT2A	Direct	gain	27	25	92.59%	474	472	99.58%	501	497	99.20%
KMT2C	Del(7q) Monosomy 7	D7S2926 & D7S2460 CEN 7	Indirect Indirect	loss loss	106 56	105 56	99.06% 100.00%	1,602 1,659	1,580 1,593	98.63% 96.02%	1,708 1,715	1,685 1,649	98.65% 96.15%
KMT2D	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	568	99.30%	698	692	99.13% 99.14%
KRAS	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	569	99.48%	698	693	99.28%
	Del(7q)	D7S2926 & D7S2460	Indirect	loss	106	104	98.11%	1,602	1,579	98.56%	1,708	1,683	98.54%
LUC7L2	Monosomy 7	CEN 7	Indirect	loss	56	55	98.21%	1,659	1,594	96.08%	1,715	1,649	96.15%
MAP3K1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	146	89.02%	1,546	1,487	96.18%	1,710	1,633	95.50%
MDM2	Trisomy 12	CEN 12	Indirect	gain	126	124	98.41%	572	563	98.43%	698	687	98.42%
	Del(7q)	D7S2460	Direct	loss	113	113	100.00%	1,593	1,582	99.31%	1,706	1,695	99.36%
MET	Del(7q)	D7S2926 & D7S2460	Indirect	loss	106	106	100.00%	1,602	1,584	98.88%	1,708	1,690	98.95%
MYC	Monosomy 7 Trisomy 8	CEN 7 CEN 8	Indirect Indirect	loss	56 93	56 89	100.00% 95.70%	1,659 1,590	1,596 1,559	96.20% 98.05%	1,715 1,683	1,652 1,648	96.33% 97.92%
NBN	Trisomy 8	CEN 8	Indirect	gain gain	93	89	95.70% 95.70%	1,590	1,559	97.55%	1,683	1,640	97.92%
NF1	Monosomy 17	NF1	Direct	loss	15	15	100.00%	908	908	100.00%	923	923	100.00%
NHP2	Del(5q)	EGR1 & RPS14	Indirect	loss	164	153	93.29%	1,546	1,496	96.77%	1,710	1,649	96.43%
NPM1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	122	74.39%	1,546	1,508	97.54%	1,710	1,630	95.32%
NSD1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	157	95.73%	1,546	1,499	96.96%	1,710	1,656	96.84%
PDGFRB	Del(5q)	EGR1 & RPS14	Indirect	loss	164	162	98.78%	1,546	1,537	99.42%	1,710	1,699	99.36%
PIK3R1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	149	90.85%	1,546	1,468	94.95%	1,710	1,617	94.56%
PMS2	Monosomy 7	CEN 7	Indirect	loss	56	51	91.07%	1,659	1,576	95.00%	1,715	1,627	94.87%
POT1	Del(7q) Monosomy 7	D7S2926 & D7S2460 CEN 7	Indirect Indirect	loss loss	106 56	102 55	96.23% 98.21%	1,602 1,659	1,582 1,599	98.75% 96.38%	1,708 1,715	1,684 1,654	98.59% 96.44%
PRPF40B	Trisomy 12	CEN 7 CEN 12	Indirect	gain	126	124	98.21% 98.41%	572	564	96.38%	698	1,654 688	96.44% 98.57%
PTPN11	Trisomy 12	CEN 12 CEN 12	Indirect	gain	120	124	98.41% 98.41%	572	567	99.13%	698	691	99.00%
RAC1	Monosomy 7	CEN 7	Indirect	loss	56	51	91.07%	1,659	1,543	93.01%	1,715	1,594	92.94%
RAD21	Trisomy 8	CEN 8	Indirect	gain	93	88	94.62%	1,590	1,581	99.43%	1,683	, 1,669	99.17%
RHEB	Del(7q)	D7S2926 & D7S2460	Indirect	loss	106	98	92.45%	1,602	1,573	98.19%	1,708	1,671	97.83%
	Monosomy 7	CEN 7	Indirect	loss	56	54	96.43%	1,659	1,590	95.84%	1,715	1,644	95.86%
			Indirect	gain	126	125	99.21%	572	563	98.43%	698	688	98.57%
RPS26	Trisomy 12	CEN 12		-	-	404	95.28%	1,602	1,570	00 000/	1,708	C	
RPS26 SAMD9	Del(7q)	D7S2926 & D7S2460	Indirect	loss	106	101				98.00%		1,671	97.83%
	Del(7q) Monosomy 7	D7S2926 & D7S2460 CEN 7	Indirect Indirect	loss	56	55	98.21%	1,659	1,583	95.42%	1,715	1,638	95.51%
	Del(7q) Monosomy 7 Del(7q)	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460	Indirect Indirect Indirect	loss loss	56 106	55 103	98.21% 97.17%	1,659 1,602	1,583 1,571	95.42% 98.06%	1,715 1,708	1,638 1,674	95.51% 98.01%
SAMD9 SAMD9L	Del(7q) Monosomy 7 Del(7q) Monosomy 7	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7	Indirect Indirect Indirect Indirect	loss loss loss	56 106 56	55 103 55	98.21% 97.17% 98.21%	1,659 1,602 1,659	1,583 1,571 1,583	95.42% 98.06% 95.42%	1,715 1,708 1,715	1,638 1,674 1,638	95.51% 98.01% 95.51%
SAMD9	Del(7q) Monosomy 7 Del(7q)	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460	Indirect Indirect Indirect	loss loss	56 106	55 103	98.21% 97.17%	1,659 1,602 1,659 1,602	1,583 1,571 1,583 1,588	95.42% 98.06%	1,715 1,708 1,715 1,708	1,638 1,674	95.51% 98.01%
SAMD9 SAMD9L	Del(7q) Monosomy 7 Del(7q) Monosomy 7 Del(7q)	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460	Indirect Indirect Indirect Indirect Indirect	loss loss loss loss	56 106 56 106	55 103 55 71	98.21% 97.17% 98.21% 66.98%	1,659 1,602 1,659	1,583 1,571 1,583	95.42% 98.06% 95.42% 99.13%	1,715 1,708 1,715	1,638 1,674 1,638 1,659	95.51% 98.01% 95.51% 97.13%
SAMD9 SAMD9L SBDS SH2B3	Del(7q) Monosomy 7 Del(7q) Monosomy 7 Del(7q) Monosomy 7	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7	Indirect Indirect Indirect Indirect Indirect Indirect	loss loss loss loss loss	56 106 56 106 56	55 103 55 71 53	98.21% 97.17% 98.21% 66.98% 94.64%	1,659 1,602 1,659 1,602 1,659	1,583 1,571 1,583 1,588 1,628	95.42% 98.06% 95.42% 99.13% 98.13%	1,715 1,708 1,715 1,708 1,715	1,638 1,674 1,638 1,659 1,681	95.51% 98.01% 95.51% 97.13% 98.02%
SAMD9 SAMD9L SBDS	Del(7q) Monosomy 7 Del(7q) Monosomy 7 Del(7q) Monosomy 7 Trisomy 12 Del(7q) Monosomy 7	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 CEN 12	Indirect Indirect Indirect Indirect Indirect Indirect	loss loss loss loss loss gain	56 106 56 106 56 126 106 56	55 103 55 71 53 124	98.21% 97.17% 98.21% 66.98% 94.64% 98.41% 97.17% 98.21%	1,659 1,602 1,659 1,602 1,659 572 1,602 1,659	1,583 1,571 1,583 1,588 1,628 566 1,576 1,591	95.42% 98.06% 95.42% 99.13% 98.13% 98.95% 98.38% 95.90%	1,715 1,708 1,715 1,708 1,715 698 1,708 1,715	1,638 1,674 1,638 1,659 1,681 690	95.51% 98.01% 95.51% 97.13% 98.02% 98.85% 98.30% 95.98%
SAMD9 SAMD9L SBDS SH2B3 SMO STAT6	Del(7q) Monosomy 7 Del(7q) Monosomy 7 Del(7q) Monosomy 7 Trisomy 12 Del(7q) Monosomy 7 Trisomy 12	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 CEN 12 D7S2926 & D7S2460 CEN 7 CEN 7	Indirect Indirect Indirect Indirect Indirect Indirect Indirect Indirect Indirect	loss loss loss loss gain loss loss gain	56 106 56 106 56 126 106 56 126	55 103 55 71 53 124 103 55 123	98.21% 97.17% 98.21% 66.98% 94.64% 98.41% 97.17% 98.21% 97.62%	1,659 1,602 1,659 1,659 572 1,602 1,602 1,659 572	1,583 1,571 1,583 1,588 1,628 566 1,576 1,591 566	95.42% 98.06% 95.42% 99.13% 98.13% 98.95% 98.38% 95.90% 98.95%	1,715 1,708 1,715 1,708 1,715 698 1,708 1,715 698	1,638 1,674 1,638 1,659 1,681 690 1,679 1,646 689	95.51% 98.01% 95.51% 97.13% 98.02% 98.85% 98.30% 95.98% 98.71%
SAMD9 SAMD9L SBDS SH2B3 SMO STAT6 TERT	Del(7q) Monosomy 7 Del(7q) Monosomy 7 Del(7q) Monosomy 7 Trisomy 12 Del(7q) Monosomy 7 Trisomy 12 Monosomy 5	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 CEN 12 D7S2926 & D7S2460 CEN 7 CEN 12 CEN 12 hTERT	Indirect Indirect Indirect Indirect Indirect Indirect Indirect Indirect Indirect Direct	loss loss loss loss gain loss loss gain loss gain	56 106 56 106 56 126 106 56 126 10	55   103   55   71   53   124   103   55   123   10	98.21% 97.17% 98.21% 66.98% 94.64% 98.41% 97.17% 98.21% 97.62% 100.00%	1,659 1,602 1,659 1,602 1,659 572 1,602 1,659 572 1,723	1,583 1,571 1,583 1,588 1,628 566 1,576 1,591 566 1,709	95.42% 98.06% 95.42% 99.13% 98.13% 98.95% 98.38% 95.90% 98.95% 99.19%	1,715 1,708 1,715 1,708 1,715 698 1,708 1,715 698 1,733	1,638 1,674 1,638 1,659 1,681 690 1,679 1,646 689 1,719	95.51% 98.01% 95.51% 97.13% 98.02% 98.85% 98.30% 95.98% 98.71% 99.19%
SAMD9 SAMD9L SBDS SH2B3 SMO STAT6	Del(7q) Monosomy 7 Del(7q) Monosomy 7 Del(7q) Monosomy 7 Trisomy 12 Del(7q) Monosomy 7 Trisomy 12	D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 D7S2926 & D7S2460 CEN 7 CEN 12 D7S2926 & D7S2460 CEN 7 CEN 7	Indirect Indirect Indirect Indirect Indirect Indirect Indirect Indirect Indirect	loss loss loss loss gain loss loss gain	56 106 56 106 56 126 106 56 126	55 103 55 71 53 124 103 55 123	98.21% 97.17% 98.21% 66.98% 94.64% 98.41% 97.17% 98.21% 97.62%	1,659 1,602 1,659 1,659 572 1,602 1,602 1,659 572	1,583 1,571 1,583 1,588 1,628 566 1,576 1,591 566	95.42% 98.06% 95.42% 99.13% 98.13% 98.95% 98.38% 95.90% 98.95%	1,715 1,708 1,715 1,708 1,715 698 1,708 1,715 698	1,638 1,674 1,638 1,659 1,681 690 1,679 1,646 689	95.51% 98.01% 95.51% 97.13% 98.02% 98.85% 98.30% 95.98% 98.71%

Cono		FISH - Positive C	ases		FISH - Negative (	Cases	FISH - All Cases				
Gene	Total Cases	Concondant	Sensitivity	Total Cases	Concondant	Specificity	Total Cases	Concondant	Accuracy		
ATM	72	72	100.00%	641	629	98.13%	713	701	98.32%		
CBFB	23	22	95.65%	517	506	97.87%	540	528	97.78%		
EGR1	171	169	98.83%	1,541	1,538	99.81%	1,712	1,707	99.71%		
KMT2A	27	25	92.59%	474	472	99.58%	501	497	99.20%		
MET	113	113	100.00%	1,593	1,582	99.31%	1,706	1,695	99.36%		
NF1	15	15	100.00%	908	908	100.00%	923	923	100.00%		
TERT	10	10	100.00%	1,723	1,709	99.19%	1,733	1,719	99.19%		
TP53	76	73	96.05%	1,567	1,556	99.30%	1,643	1,629	99.15%		

### **Direct vs Indirect FISH Markers**

Cono	FISH Test	FISH Probes	Strategy	Direction		Positive (	Cases	1	Negative (	Cases	All Cases		
Gene	risn Test			Direction	Total	Conc.	Sensitivity	Total	Conc.	Specificity	Total	Conc.	Accuracy
ECD1	Del(5q)	EGR1	Direct	loss	171	169	98.83%	1,541	1,538	99.81%	1,712	1,707	99.71%
EGR1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	162	98.78%	1,546	1,538	99.48%	1,710	1,700	99.42%
	Del(7q)	D7S2460	Direct	loss	113	113	100.00%	1,593	1,582	99.31%	1,706	1,695	99.36%
MET	Del(7q)	D7S2926 & D7S2460	Indirect	loss	106	106	100.00%	1,602	1,584	98.88%	1,708	1,690	98.95%
	Monosomy 7	CEN 7	Indirect	loss	56	56	100.00%	1,659	1,596	96.20%	1,715	1,652	96.33%

<b>C</b>	Cataband	Strategy	Direction		FISH Probe CEN 7		FISH Probes D7S2926 & D7S2460				
Gene	Cytoband			Sensitivity	Specificity	Accuracy	Sensitivity	Specificity	Accuracy		
GNA12	7p22.3	Indirect	loss	91.07%	96.44%	96.27%	N/A	N/A	N/A		
CARD11	7p22.2	Indirect	loss	92.86%	98.61%	98.43%	N/A	N/A	N/A		
PMS2	7p22.1	Indirect	loss	91.07%	95.00%	94.87%	N/A	N/A	N/A		
RAC1	7p22.1	Indirect	loss	91.07%	93.01%	92.94%	N/A	N/A	N/A		
IKZF1	7p12.2	Indirect	loss	96.43%	96.62%	96.62%	N/A	N/A	N/A		
EGFR	7p11.2	Indirect	loss	96.43%	97.71%	97.67%	N/A	N/A	N/A		
				FISH	PROBE 1 (CEN 7)						
SBDS	7q11.21	Indirect	loss	94.64%	98.13%	98.02%	66.98%	99.13%	97.13%		
CDK6	7q21.2	Indirect	loss	98.21%	96.38%	96.44%	94.34%	98.81%	98.54%		
SAMD9	7q21.2	Indirect	loss	98.21%	95.42%	95.51%	95.28%	98.00%	97.83%		
SAMD9L	7q21.2	Indirect	loss	98.21%	95.42%	95.51%	97.17%	98.06%	98.01%		
CUX1	7q22.1	Indirect	loss	98.21%	95.42%	95.51%	97.17%	98.06%	98.01%		
				FISH P	ROBE 2 (D7S2926)						
MET	7q31.2	Indirect	loss	100.00%	96.20%	96.33%	100.00%	98.88%	98.95%		
				FISH P	ROBE 3 (D7S2460)						
POT1	7q31.33	Indirect	loss	98.21%	96.38%	96.44%	96.23%	98.75%	98.59%		
SMO	7q32.1	Indirect	loss	98.21%	95.90%	95.98%	97.17%	98.38%	98.30%		
LUC7L2	7q34	Indirect	loss	98.21%	96.08%	96.15%	98.11%	98.56%	98.54%		
BRAF	7q34	Indirect	loss	100.00%	96.02%	96.15%	100.00%	98.69%	98.77%		
EZH2	7q36.1	Indirect	loss	98.21%	96.02%	96.09%	98.11%	98.56%	98.54%		
RHEB	7q36.1	Indirect	loss	96.43%	95.84%	95.86%	92.45%	98.19%	97.83%		
KMT2C	7q36.1	Indirect	loss	100.00%	96.02%	96.15%	99.06%	98.63%	98.65%		

# NGS performances vs FISH probes position (arm 5q)

Como	Cutaband		FISH Probes	Strategy	Direction	Positive Cases			N	legative	Cases	All Cases		
Gene	Cytoband	FISH Test				Total	Conc.	Sensitivity	Total	Conc.	Specificity	Total	Conc.	Accuracy
MAP3K1	5q11.2	Del(5q)	EGR1 & RPS14	Indirect	loss	164	146	89.02%	1,546	1,487	96.18%	1,710	1,633	95.50%
PIK3R1	5q13.1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	149	90.85%	1,546	1,468	94.95%	1,710	1,617	94.56%
APC	5q22.2	Del(5q)	EGR1 & RPS14	Indirect	loss	164	155	94.51%	1,546	1,525	98.64%	1,710	1,680	98.25%
CDC25C	5q31.2	Del(5q)	EGR1 & RPS14	Indirect	loss	164	161	98.17%	1,546	1,533	99.16%	1,710	1,694	99.06%
					FISH PR	OBE 1 (E	GR1)							
EGR1	5q31.2	Del(5q)	EGR1 & RPS14	Indirect	loss	164	162	98.78%	1,546	1,538	99.48%	1,710	1,700	99.42%
CSF1R	5q32	Del(5q)	EGR1 & RPS14	Indirect	loss	164	162	98.78%	1,546	1,538	99.48%	1,710	1,700	99.42%
PDGFRB	5q32	Del(5q)	EGR1 & RPS14	Indirect	loss	164	162	98.78%	1,546	1,537	99.42%	1,710	1,699	99.36%
					FISH PRO	DBE 2 (R	PS14)							
EBF1	5q33.3	Del(5q)	EGR1 & RPS14	Indirect	loss	164	151	92.07%	1,546	1,477	95.54%	1,710	1,628	95.20%
NPM1	5q35.1	Del(5q)	EGR1 & RPS14	Indirect	loss	164	122	74.39%	1,546	1,508	97.54%	1,710	1,630	95.32%
NSD1	5q35.3	Del(5q)	EGR1 & RPS14	Indirect	loss	164	157	95.73%	1,546	1,499	96.96%	1,710	1,656	96.84%
DDX41	5q35.3	Del(5q)	EGR1 & RPS14	Indirect	loss	164	143	87.20%	1,546	1,528	98.84%	1,710	1,671	97.72%
NHP2	5q35.3	Del(5q)	EGR1 & RPS14	Indirect	loss	164	153	93.29%	1,546	1,496	96.77%	1,710	1,649	96.43%

# References

[2] Talevich E, Shain AH, Botton T, Bastian BC (2014). CNVkit: Genome-wide copy number detection and visualization from targeted sequencing. PLOS Computational Biology, 12, 4.



# Validation results for genes with a direct FISH Marker

# NGS performances vs FISH probes position (chromosome 7)

[1] Riester M, Singh A, Brannon A, Yu K, Campbell C, Chiang D, Morrissey M (2016). PureCN: Copy number calling and SNV classification using targeted short read sequencing. Source Code for Biology and Medicine, 11, 13.